Compugen Ltd. Stock
Compugen Ltd. Stock
A loss of -1.920% shows a downward development for Compugen Ltd..
The community is currently still undecided about Compugen Ltd. with 1 Buy predictions and 0 Sell predictions.
With a target price of 5 € there is potential for a 142.72% increase which would mean more than doubling the current price of 2.06 € for Compugen Ltd..
Pros and Cons of Compugen Ltd. in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Compugen Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Compugen Ltd. | -1.920% | -0.962% | 16.384% | 56.535% | 56.535% | 106.000% | -63.860% |
| Protalix Biotherapeutics Inc. | -3.350% | -0.713% | 7.732% | 58.333% | 36.601% | 54.472% | 48.227% |
| Chromadex Corp | 0.000% | -4.196% | -4.196% | -65.316% | -50.182% | 82.667% | -67.765% |
| Intellia Therapeutics Inc | 1.060% | -5.126% | -33.050% | -18.445% | 20.933% | -74.773% | -91.932% |
Comments
Compugen (CGEN) is now covered by Lake Street Capital. They set a "buy" rating and a $6.00 price target on the stock.
Show more
Ratings data for CGEN provided by MarketBeat
Compugen Ltd. (NASDAQ: CGEN) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $4.00 price target on the stock.
Show more
Ratings data for CGEN provided by MarketBeat
Compugen Ltd. (NASDAQ: CGEN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for CGEN provided by MarketBeat
News
Compugen Q1 Earnings Call Highlights
Key Points
- Interested in Compugen Ltd.? Here are five stocks we like better.
- COM701 ovarian trial is on schedule: Compugen said all sites are open and enrolling in its MAIA-ovarian study, and
